CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 70 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04324151
NCT04324151N/ARecruitingUpdate OverdueUpdated 21mo ago · Completion was 18mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Hunan Province Tumor Hospital·observational·Posted Mar 27, 2020·Updated Sep 19, 2024

In Brief

An observational study for Non Small Cell Lung Cancer. Currently recruiting, targeting 70 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

N/ARecruitingOverdue
202120222023202420252026
First PostedMar 27, 2020
Enrollment StartMar 24, 2020
Primary CompletionDec 24, 2024
Study CompletionMar 24, 2025
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 6.3 years ago